“…As the nonspecific immunomodulator we chose the MVE-2 due to its superiority to some other nonspecific immunomodulators (e.g. BCG, MDP) in triggering of the anti-tumor immune response in combination with irradiated tumor cells [12]. The aim of this study was thus to determine the capability of DC stimulated through the irradiated tumor cells and MVE-2 in inducing the activation of T cells.…”